Sean Martin - 26 Feb 2026 Form 4 Insider Report for Generate Biomedicines, Inc. (GENB)

Reporting relationship: Chief Legal Officer & GC
Issuer ticker: GENB
Reported as of: 26 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Mar 2026, 17:58:03 UTC
Prior SEC filing: 04 Mar 2022
Source filing: View source filing
Reporting owner signature: /s/ Michael Wolf, Attorney-in-Fact

Key filing fact

Sean Martin filed Form 4 for Generate Biomedicines, Inc. (GENB) on 02 Mar 2026.

Key facts

This page summarizes Sean Martin's Form 4 filing for Generate Biomedicines, Inc. (GENB).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Mar 2026, 17:58.

Change

Previous filing in this sequence was filed on 04 Mar 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001500332 Primary reporting owner

Martin Sean

Relationship: Chief Legal Officer & GC
Address: GENERATE BIOMEDICINES, INC., 101 SOUTH STREET, SUITE 900, SOMERVILLE
Signature: /s/ Michael Wolf, Attorney-in-Fact
Signature date: 02 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GENB transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +190,034
Change %
Price: $0.000000
Shares after: 190,034
Date: 26 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 190,034
Exercise price: $16.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying this option shall vest in forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.